Eli Lilly & Co. vs. Mineralys Therapeutics, Inc. Common Stock
Eli Lilly & Co. (LLY) comes out ahead, leading on 4 of 6 compared factors.
Size & Scale
| LLY | MLYS | |
|---|---|---|
| Market Cap | $1.03 trillion | $2.50 billion |
| Revenue (TTM) | $79.67 billion | — |
| Net Income (TTM) | $26.71 billion | $-349,576,000 |
LLY leads on 3 of 3 size & scale factors.
Valuation
| LLY | MLYS | |
|---|---|---|
| P/E Ratio | 38.93 | — |
| Price / Book | 30.52 | 4.54 |
| Price / Sales | 12.98 | — |
MLYS leads on 1 of 1 valuation factors.
Profitability
| LLY | MLYS | |
|---|---|---|
| Net Margin | 33.53% | — |
| Return on Equity | 78.84% | -63.45% |
LLY leads on 1 of 1 profitability factors.
Dividend
| LLY | MLYS | |
|---|---|---|
| Dividend Yield | 0.60% | — |
| Payout Ratio | 23.23 | — |
LLY and MLYS split the dividend factors evenly.
Risk & Sentiment
| LLY | MLYS | |
|---|---|---|
| Short Interest | 1.29% | 0.06% |
MLYS leads on 1 of 1 risk & sentiment factors.
Dig deeper: LLY overview, LLY financials, MLYS overview, MLYS financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.